ES2013667A6 - Procedimiento para obtener un preparado farmaceutico liofilizado de factor de necrosis de tumores. - Google Patents

Procedimiento para obtener un preparado farmaceutico liofilizado de factor de necrosis de tumores.

Info

Publication number
ES2013667A6
ES2013667A6 ES8901300A ES8901300A ES2013667A6 ES 2013667 A6 ES2013667 A6 ES 2013667A6 ES 8901300 A ES8901300 A ES 8901300A ES 8901300 A ES8901300 A ES 8901300A ES 2013667 A6 ES2013667 A6 ES 2013667A6
Authority
ES
Spain
Prior art keywords
necrosis factor
tumor necrosis
factor formulations
formulations
formulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES8901300A
Other languages
English (en)
Inventor
Maninder Singh Hora
Flint William Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cetus Oncology Corp
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of ES2013667A6 publication Critical patent/ES2013667A6/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROCEDIMIENTO PARA OBTENER UN PREPARADO FARMACEUTICO LIOFILIZADO DE FACTOR DE NECROSIS DE TUMORES. CONSISTE EN MEZCLAR, A APROXIMADAMENTE LA TEMPERATURA AMBIENTE, 1) UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE FACTOR DE NECROSIS DE TUMORES, 2) UN MATERIAL ESTABILIZADOR FISIOLOGICAMENTE ACEPTABLE SELECCIONADO ENTRE PROTEINAS, POLISACARIDOS, POLIMEROS HIDROFILOS ORGANICOS Y OLIGOSACARIDOS, 3) UN TAMPON FISIOLOGICAMENTE ACEPTABLE Y 4) UNA CANTIDAD EFICAZ DE UN SOLUTO DE CRISTALIZACION FISIOLOGICAMENTE ACEPTABLE, EMPLEANDOSE DICHO SOLUTO DE CRISTALIZACION, CUANDO EL MATERIAL ESTABILIZADOR ES UN OLIGOSACARIDO, EN UNA RELACION EN PESO CON EL OLIGOSACARIDO DE AL MENOS 2:1; FILTRAR LA MEZCLA EN CONDICIONES ESTERILES A APROXIMADAMENTE LA TEMPERATURA AMBIENTE; Y LIOFILIZAR LA MEZCLA CONGELANDOLA PRIMERO Y SECANDOLA SEGUIDAMENTE A UNA TEMPERATURA INFERIOR A 0GC. LOS PREPARADOS OBTENIDOS SON UTILES COMO AGENTES INMUNOLOGICOS ADMINISTRABLES POR VIA PARENTERAL.
ES8901300A 1988-04-13 1989-04-13 Procedimiento para obtener un preparado farmaceutico liofilizado de factor de necrosis de tumores. Expired - Fee Related ES2013667A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/181,077 US5215743A (en) 1988-04-13 1988-04-13 Tumor necrosis factor formulations

Publications (1)

Publication Number Publication Date
ES2013667A6 true ES2013667A6 (es) 1990-05-16

Family

ID=22662812

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8901300A Expired - Fee Related ES2013667A6 (es) 1988-04-13 1989-04-13 Procedimiento para obtener un preparado farmaceutico liofilizado de factor de necrosis de tumores.

Country Status (8)

Country Link
US (1) US5215743A (es)
EP (1) EP0423244B1 (es)
JP (1) JPH03504721A (es)
AU (1) AU3447389A (es)
DE (1) DE68913537D1 (es)
ES (1) ES2013667A6 (es)
IL (1) IL89930A0 (es)
WO (1) WO1989009610A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
WO1991002531A1 (en) * 1989-08-17 1991-03-07 Peter Maccallum Cancer Institute Method for the modulation of haemopoiesis in a mammal
AU2309692A (en) * 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
FR2684878B1 (fr) * 1991-12-12 1994-02-11 Roussel Uclaf Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US20020031563A1 (en) * 1992-09-30 2002-03-14 Hodge Thomas W. Method of inhibiting tumor necrosis factor
JPH0776527A (ja) * 1993-06-28 1995-03-20 Hayashibara Biochem Lab Inc 半固形製剤とその製造方法
US6270757B1 (en) * 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
RU2065307C1 (ru) * 1994-12-13 1996-08-20 Александр Васильевич Тихонов Способ лечения первичного рака печени и набор для лечения первичного рака печени
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
US6126933A (en) * 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US6540993B1 (en) * 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AUPO066096A0 (en) * 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
WO1999018119A1 (en) * 1997-10-03 1999-04-15 Shionogi & Co., Ltd. Process for freeze-drying proteins
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US20030009013A1 (en) * 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2003037375A1 (fr) * 2001-11-02 2003-05-08 Sekisui Chemical Co., Ltd. Substance d'induction de cytokine et instrument d'induction de cytokine
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
WO2004045376A2 (en) * 2002-11-15 2004-06-03 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
EP2266599B1 (en) 2004-07-26 2014-04-16 Merz Pharma GmbH & Co. KGaA Therapeutic composition with a botulinum neurotoxin
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
CA2677937A1 (en) * 2007-02-16 2008-08-21 Wyeth Use of sucrose to suppress mannitol-induced protein aggregation
AU2010221156A1 (en) * 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
EP3738605A1 (en) 2012-09-10 2020-11-18 Xencor, Inc. Methods of treating neurological diseases
MX366622B (es) 2012-10-26 2019-07-16 Lupin Atlantis Holdings Sa Composicion farmaceutica estable de la proteina de fusion tnfr:fc.
EP3936137A1 (en) 2013-02-07 2022-01-12 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
CN104274827B (zh) * 2013-07-01 2020-07-14 上海贺普药业股份有限公司 贺普拉肽的制剂
CN111879948A (zh) 2013-10-17 2020-11-03 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
TWI593967B (zh) * 2014-05-01 2017-08-01 高雄醫學大學 二級抗體所辨識之抗原決定位及其用途
CN115043943A (zh) 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
US10519207B2 (en) 2015-06-12 2019-12-31 Georgia State University Research Foundation, Inc. Compositions and methods for treating opioid tolerance
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
EP3355914B1 (en) 2015-09-29 2024-03-06 The General Hospital Corporation A composition comprising bcg for reducing cholesterol.
US11859002B2 (en) 2016-05-13 2024-01-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies
CN106729633A (zh) * 2017-03-03 2017-05-31 上海唯科生物制药有限公司 一种肿瘤坏死因子直肠给药制剂及其制备方法
CN106620656A (zh) * 2017-03-03 2017-05-10 上海唯科生物制药有限公司 一种肿瘤坏死因子舌下给药制剂及其制备方法
CN113302205B (zh) 2018-11-15 2024-12-06 综合医院公司 激动性肿瘤坏死因子受体超家族多肽
CN111110638B (zh) * 2020-01-10 2022-10-14 广州市丹蓝生物科技有限公司 一种偶联有蛋白的微球冻干制剂及其制备方法、保存方式

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU189251B (en) * 1982-04-07 1986-06-30 Asahi Kasei Kogyo Kk,Jp Process for stabilizing tumor necrosis factor
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
US4797388A (en) * 1984-05-21 1989-01-10 Cetus Corporation Pharmaceutical compositions with galactitol as carrier
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
JPH0710342B2 (ja) * 1985-12-26 1995-02-08 株式会社林原生物化学研究所 無水アルドヘキソ−スによる含水物の脱水方法
US4762857A (en) * 1986-05-30 1988-08-09 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient

Also Published As

Publication number Publication date
DE68913537D1 (de) 1994-04-07
EP0423244A1 (en) 1991-04-24
IL89930A0 (en) 1989-12-15
AU3447389A (en) 1989-11-03
US5215743A (en) 1993-06-01
EP0423244B1 (en) 1994-03-02
JPH03504721A (ja) 1991-10-17
WO1989009610A1 (en) 1989-10-19

Similar Documents

Publication Publication Date Title
ES2013667A6 (es) Procedimiento para obtener un preparado farmaceutico liofilizado de factor de necrosis de tumores.
BG108927A (en) INBIEBLES OF INTERLEVKIN - 1BETA - CONVERTING ENZYME, METHOD OF RECEIVING THEM, PHARMACEUTICAL COMPOSITION THAT CONTAINS AND USING THEM AS MEDICINAL
EG18334A (en) Pyrozoline compounds and their use as pesticides
IL74497A (en) Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
NZ225491A (en) Benzamide derivatives, their preparation and plant growth regulating compositions
MY101791A (en) New benzimidazole derivatives
AU5490886A (en) Phenoxyalkylaminopyrimidine derivatives, their preparation and insecticidal and acaricidal compositions containing them
IL77396A (en) Pharmaceutical compositions containing bicyclic heteroarylpiperazine derivatives,certain such novel compounds and their preparation
NZ240230A (en) Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
IL85989A (en) Leukotriene antagonistic polysubstituted acylphenols, their preparation, pharmaceutical compositions containing them and some intermediates therefor
IL94433A0 (en) Aminophenol derivatives,their preparation and pharmaceutical compositions containing them
IL75197A0 (en) Aminotetralin derivatives,their preparation and pharmaceutical compositions containing them
FI892454A0 (fi) Nya bensimidazolderivat, foerfarande foer framstaellning av desamma och farmaceutisk komposition innehaollande desamma.
IL74222A (en) 6-substituted-4-dialkylamino tetrahydrobenz(c,d)indoles,their preparation and pharmaceutical compositions comprising them
ATE26115T1 (de) Substituierte 8-phenylxanthine.
EP0321968A3 (en) Compounds active on the cardiovascular system
DE3572977D1 (en) Indole derivatives, their preparation, their use as medicines and compositions containing them
FI853648L (fi) Foerfarande foer framstaellning av farmaceutiskt aktiva 4,5-dihydro-4-okso-2-/(2-trans-fenylcyklopropyl) amino/-3-furankarboxylsyror och derivat daerav.
IL85189A (en) Beta-alkyl substituted melatonins,their preparation and pharmaceutical compositions containing them
IL111966A0 (en) 4-Benzoylisoxazole derivatives, their preparation and herbicidal compositions containing them
ES8405054A1 (es) Procedimiento para la obtencion de granulados dispersables o bien solubles en agua.
ATE13184T1 (de) Aldehydaddukte des triamterens und sie enthaltende pharmazeutische zusammensetzungen.
ZA891783B (en) Peptides with pharmaceutical activity
IL76452A0 (en) Vinylphenyl substituted tetrazol derivatives,their preparation and pharmaceutical compositions containing them
ES8706138A1 (es) Procedimiento para la obtencion de nuevas benzoilureas

Legal Events

Date Code Title Description
PC1A Transfer granted

Owner name: CETUS ONCOLOGY CORPORATION

PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20041102